KRAS and neoplasm: In conclusion, we designed and constructed a DNA/γPNA hybrid nanoreporter that can specifically recognize and record KRAS(G12D) mutation in peripheral blood, allowing for urinary monitoring of tumor‐associated DNA mutation via γPNA urinalysis.